berberine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases colorectal adenoma recurrence after polypectomy
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Sensitivity analyses also demonstrated the same trend: patients in the berberine group had lower risk of colorectal adenoma recurrence (adjusted HR, 0.62; 95% CI: 0.49–0.79; p < 0.001) (Table S2).”
Quoted verbatim from Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.. - Study
- cohort
- Population
- Patients with resected colorectal adenoma from the CBAR trial, extended 6-year post-treatment follow-up (CBAR-FE study); sensitivity-analysis estimate
Effect 0.62 hazard ratio, 95% CI 0.49 to 0.79
Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.2025PMID:40795846Permalink
Keep reading
- Everything the graph holds on berberine
- Every compound studied against Colorectal adenoma recurrence after polypectomy
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M2SDD0C8TJ3MNKCF2ATHM1S7